



Edition: BP 2025 (Ph. Eur. 11.6 update)

## Iopamidol Injection

### [General Notices](#)

#### Action and use

Iodinated contrast medium.

### DEFINITION

Iopamidol Injection is a solution of Iopamidol in Water for Injections with or without [excipients](#).

*The injection complies with the requirements stated under [Parenteral Preparations](#) and with the following requirements.*

#### Content of Iopamidol, $C_{17}H_{22}I_3N_3O_8$

95.0 to 105.0% of the stated amount.

### IDENTIFICATION

- A. Dry 1 mL of the injection over [phosphorus pentoxide](#) at a pressure of 2 kPa for 16 hours. The [infrared absorption spectrum](#) of the dried residue, [Appendix II A](#), is concordant with the *reference spectrum* of Iopamidol ([RS 441](#)).
- B. In the test for Related substances, the principal peak in the chromatogram obtained with solution (1) corresponds to that in the chromatogram obtained with solution (5).

### TESTS

#### Acidity or alkalinity

pH, 6.5 to 7.5, [Appendix V L](#).

#### [Light absorption](#)

The [light absorption](#) of a 4-cm layer of the injection, [Appendix II B](#) at 450 nm is not more than 0.120.

#### Free aromatic amines

*The following solutions and reagents are stored in ice-water and protected from bright light.*

Mix a volume of the injection containing 0.5 g of Iopamidol with [water](#) and add sufficient [water](#) to produce 20 mL. Place the solution in ice-water, protected from light, for 5 minutes. Add 1.0 mL of [hydrochloric acid](#), mix and allow to stand for 5 minutes. Add 1.0 mL of a 2% w/v solution of [sodium nitrite](#) prepared immediately before use, mix and allow to stand for 5 minutes. Add 1.0 mL of a 12% w/v solution of [ammonium sulfamate](#), swirl gently until gas liberation has ceased and allow to stand for 5 minutes. Add 1.0 mL of a freshly prepared 0.1% w/v solution of [naphthylethylenediamine dihydrochloride](#) and mix. Remove from the ice-water and allow to stand for 10 minutes. Add sufficient [water](#) to produce 25 mL and mix.

Immediately measure the [absorbance](#) at 500 nm, [Appendix II B](#), using in the reference cell a solution prepared by treating 20 mL of [water](#) in the same manner.

The [absorbance](#) is not greater than that obtained by treating 20 mL of a 0.00125% w/v solution of [iopamidol impurity A EPCRS](#) in [water](#) in the same manner and beginning at the words "Place the solution..." (500 ppm).

### Free iodine

Mix a volume of the injection containing 2.0 g of Iopamidol with [water](#) and add sufficient [water](#) to produce 25 mL. Add 5 mL of [toluene](#) and 5 mL of [dilute sulfuric acid](#), shake and centrifuge. Any red colour in the upper phase is not more intense than that of the upper phase obtained in the same manner from a mixture of 22 mL of [water](#), 2 mL of [iodide standard solution \(10 ppm I\)](#), 5 mL of [dilute sulfuric acid](#), 1 mL of [hydrogen peroxide solution \(100 vol\)](#), and 5 mL of [toluene](#) (10 ppm).

### Iodide

To 10 mL of the injection add sufficient [water](#) to produce 50 mL. Add 2.0 mL of [0.001M potassium iodide](#). Carry out the method for [potentiometric titration, Appendix VIII B](#), using 0.001M [silver nitrate VS](#), a silver indicator electrode and an appropriate reference electrode. Subtract the volume of titrant corresponding to the 2.0 mL of [0.001M potassium iodide](#), determined by titrating a blank to which is added 2.0 mL of 0.001M [potassium iodide](#), and use the residual value to calculate the iodide content.

1 mL of [0.001M silver nitrate VS](#) is equivalent to 126.9 µg of iodide.

Not more than 2.0 mL of [0.001M silver nitrate VS](#) is required (40 ppm).

### Related substances

Carry out the method for [liquid chromatography, Appendix III D](#), using the following solutions.

- (1) Mix a volume of the injection containing 0.5 g of Iopamidol with [water](#) and add sufficient [water](#) to produce 50 mL.
- (2) 0.005% w/v of [iopamidol impurity H EPCRS](#) in [water](#).
- (3) Dilute 1 volume of solution (1) to 500 volumes with [water](#).
- (4) To 200 volumes of solution (2) add 1 volume of solution (1) and add sufficient [water](#) to produce 500 volumes.
- (5) 1.0% w/v of [iopamidol EPCRS](#) in [water](#).

### CHROMATOGRAPHIC CONDITIONS

- (a) Use two stainless steel columns (25 cm × 4.6 mm) coupled in series and packed with [phenylsilyl silica gel for chromatography](#) (5 µm) (Zorbax SB-Phenyl 80 Å is suitable).
- (b) Use gradient elution and the mobile phase described below.
- (c) Use a flow rate of 2.0 mL per minute.
- (d) Use a column temperature of 60°.
- (e) Use a detection wavelength of 240 nm.
- (f) Inject 20 µL of each solution.

The retention time of Iopamidol is about 15 minutes and the retention time of the peak due to impurity H is about 13 minutes. Impurity H and impurity I have identical retention times.

### MOBILE PHASE

Mobile phase A [water](#).

Mobile phase B Equal volumes of [acetonitrile](#) and [water](#).

Equilibrate the column for at least 20 minutes with mobile phase A.

Time (Minutes)	Mobile phase A (%v/v)	Mobile phase B (%v/v)	Comment
0-18	100	0	isocratic
18-40	100→62	0→38	linear gradient
40-45	62→50	38→50	linear gradient
45-50	50→100	50→0	linear gradient
50-60	100	0	re-equilibration

#### SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (4), the [resolution factor](#) between the peaks corresponding to iopamidol and iopamidol impurity H is at least 2.0. If necessary, adjust the composition of the mobile phase or the time programme of the gradient.

#### LIMITS

In the chromatogram obtained with solution (1):

the area of any peak corresponding to impurity H or impurity I is not greater than 2.5 times the area of the principal peak in the chromatogram obtained with solution (3) (0.5%);

the area of any other [secondary peak](#) is not greater than half the area of the principal peak in the chromatogram obtained with solution (3) (0.1%);

the sum of the areas of any [secondary peaks](#) other than impurities H and I is not greater than the area of the principal peak in the chromatogram obtained with solution (3) (0.2%).

Disregard any peak with an area less than 0.25 times the area of the principal peak in the chromatogram obtained with solution (3) (0.05%).

#### [Sterility](#)

Complies with the test for [sterility](#), [Appendix XVI A](#).

#### [Bacterial endotoxins](#)

The endotoxin limit concentration is 0.7 IU per mL, [Appendix XIV C](#).

## ASSAY

Mix a volume of the injection containing 0.220 g of iopamidol with [water](#) and add sufficient [water](#) to produce 20 mL. Add 5 mL of [strong sodium hydroxide solution](#), 1 g of [zinc powder](#) and a few glass beads. Boil under a reflux condenser for 30 minutes. Allow to cool and rinse the condenser with 20 mL of [water](#), adding the rinsings to the flask. Filter through a sintered-glass filter and wash the filter with several quantities of [water](#). Collect the filtrate and washings. Add 5 mL of [glacial acetic acid](#) and titrate immediately with [0.1M silver nitrate VS](#). Carry out the method for [potentiometric titration](#), [Appendix VIII B](#), using a suitable electrode system such as silver-silver chloride.

Each mL of [0.1M silver nitrate VS](#) is equivalent to 25.90 mg of  $C_{17}H_{22}I_3N_3O_8$ .

## STORAGE

Iopamidol Injection should be protected from light.

## **LABELLING**

The quantity of active ingredient is stated in terms of lopamidol and as the equivalent amount of iodine.

## **IMPURITIES**

The impurities limited by the requirements of this monograph include those listed under lopamidol.